Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets (Q36574553)

15 August 2017

title

Ubiquitylation in normal and malignant hematopoiesis: novel therapeutic targets (English)

1 reference

15 August 2017

0 references

1 reference

Marteijn JA

1

1 reference

15 August 2017

Jansen JH

series ordinal

2

1 reference

15 August 2017

van der Reijden BA

series ordinal

3

1 reference

15 August 2017

publication date

27 July 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

20

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1511-1518

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404319

15 August 2017

exact match

0 references

cites work

A field guide to ubiquitylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Back to the future with ubiquitin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Ubiquitylation and cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The novel functions of ubiquitination in signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Regulation of DNA repair by ubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Ubiquitin signalling in the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Differential modification of Ras proteins by ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Polyubiquitin chains: polymeric protein signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Proteolysis: The proteasome: a protein-degrading organelle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The proteasome: a suitable antineoplastic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Proteasomes: a complex story.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

A genomic and functional inventory of deubiquitinating enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The deubiquitinating enzyme DUB-2 prolongs cytokine-induced signal transducers and activators of transcription activation and suppresses apoptosis following cytokine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Productive RUPture: activation of transcription factors by proteasomal processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Disruption of differentiation in human cancer: AML shows the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Rapid turnover of GATA-2 via ubiquitin-proteasome protein degradation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBPalpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Diminished proteasomal degradation results in accumulation of Gfi1 protein in monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Enforced expression of CUL-4A interferes with granulocytic differentiation and exit from the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

CUL-4A stimulates ubiquitylation and degradation of the HOXA9 homeodomain protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

SOCS: role in inflammation, allergy and homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Defective downregulation of receptor tyrosine kinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

When protein destruction runs amok, malignancy is on the loose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The Fanconi anaemia/BRCA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

ERAD: the long road to destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Progressively impaired proteasomal capacity during terminal plasma cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

The proteasome and proteasome inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

Bortezomib: proteasome inhibition as an effective anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404319

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.LEU.2404319

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7eikyjoqjzdi5mjkzkh3tnt664

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_7eikyjoqjzdi5mjkzkh3tnt664

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7eikyjoqjzdi5mjkzkh3tnt664

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/7eikyjoqjzdi5mjkzkh3tnt664

1 reference

30 July 2022